EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer

Zhan Shi, Yan Wang, Yumeng Wang, Shutong Liu, Lianru Zhang, Kai Xin, Baorui Liu, Qin Liu iD

Current Oncology · 2025

DOI: 10.3390/curroncol33010002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Zhan Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Esophagogastric Junction, Immunoconjugates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Province 333 project, Jiangsu provincial medical key discipline during the "14th Five-Year Plan" period, Nanjing Medical Key Laboratory of Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the real-world efficacy and safety of disitamab vedotin (RC48-ADC) in patients with human epidermal growth factor receptor 2 (HER2) overexpression (immunohistochemistry [IHC] 2+ or 3+), advanced gastric/gastroesophageal junction cancer (GC/GEJC) with metastases who had received at least one line of prior systemic therapy. Patients and methods: Patients with HER2-overexpressing advanced or metastatic GC/GEJC who had previously received the anti-HER2 antibody-drug conjugate disitamab vedotin between December 2022 and April 2024 were enrolled in this study. The patients’ baseline characteristics, treatment procedures, and laboratory or imaging examinations were retrospectively collected and analyzed. The observation items included the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs).

Results

Of the 38 enrolled patients in the study, 27 were found to be HER2-positive. Most patients (29/38) received disitamab vedotin therapy as a third-line or subsequent treatment. A total of 68.4% of patients had previously received anti-HER2 therapy, and 13 patients underwent immunotherapy concurrently. The overall ORR and DCR were 31.6% and 65.8%, respectively. A higher ORR was observed in patients with a single metastatic site compared to those with multiple sites (53.3% vs. 17.4%, p = 0.022). In the general population, the median PFS was 6.5 months (95% confidence interval [CI] 3.3–9.8 months), and OS was 13.5 months (95% CI 9.0–17.9 months). The most common adverse event was anemia (89.5%), and eight patients suffered severe toxicities of grade ≥3.

Conclusions

Disitamab vedotin exhibited encouraging anti-tumor effectiveness with a tolerable safety profile for advanced GC/GEJC patients with HER2 overexpression who had failed at least one line of systemic therapy in a real-world setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErb-b2 Receptor Tyrosine KinasesEsophagogastric JunctionImmunoconjugatesEsophageal NeoplasmsHumansFemaleMiddle AgedMaleAgedRetrospective StudiesAdultTreatment OutcomeAntibodies, MonoclonalOligopeptides

Stichwörter der Autor:innen

HER2disitamab vedotinefficacygastric/gastroesophageal junction cancersafety

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanImmunoconjugatesdisitamab vedotinAntibodies, MonoclonalOligopeptides

Autor:innen und Institutionen

  • Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.

ORCID-Profile: Qin Liu

Förderung

  • Jiangsu Province 333 project
  • Jiangsu provincial medical key discipline during the "14th Five-Year Plan" period
  • Nanjing Medical Key Laboratory of Oncology
  • Jiangsu provincial medical key discipline during the “14th Five-Year Plan” period
  • National Natural Science Foundation of China
  • Young Scholars of Jiangsu Province

Zitieren

APA

Shi, Z., Wang, Y., Wang, Y., Liu, S., Zhang, L., Xin, K., Liu, B., & Liu, Q. (2025). Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer. Current Oncology. https://doi.org/10.3390/curroncol33010002

Vancouver

Shi Z, Wang Y, Wang Y, Liu S, Zhang L, Xin K, et al. Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer. Current Oncology. 2025. doi:10.3390/curroncol33010002

BibTeX
@article{Shi2025,
  author = {Shi, Zhan and Wang, Yan and Wang, Yumeng and Liu, Shutong and Zhang, Lianru and Xin, Kai and Liu, Baorui and Liu, Qin},
  title = {Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol33010002}
}
Kostenlos starten →